Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | RECQL | P46063 | 2/20 | 1.00 |
| ▸ | SOST | Q9BQB4 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | ALOX12 | P18054 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | SYNJ2 | O15056 | 3/20 | 0.75 |
| ▸ | APP | P05067 | 1/20 | 0.75 |
| ▸ | XDH | P47989 | 2/20 | 0.67 |
| ▸ | IDO1 | P14902 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Taxifolin SCHEMBL29390633 | 1.00 | CYP3A4 (1.00) | CYP3A4ALOX15MAPTHSD17B10RECQL | |
| (+)-Taxifolin SCHEMBL30300501 | 1.00 | CYP3A4 (1.00) | CYP3A4ALOX15MAPTHSD17B10RECQL | |
| (+)-Taxifolin SCHEMBL30631315 | 1.00 | CYP3A4 (1.00) | CYP3A4ALOX15MAPTHSD17B10RECQL | |
| (+)-Epitaxifolin SCHEMBL31575455 | 1.00 | CYP3A4 (1.00) | CYP3A4ALOX15MAPTHSD17B10RECQL | |
| (+)-Taxifolin SCHEMBL29361519 | 1.00 | CYP3A4 (1.00) | CYP3A4ALOX15MAPTHSD17B10RECQL | |
| (+)-Taxifolin SCHEMBL13241264 | 1.00 | CYP3A4 (1.00) | CYP3A4ALOX15MAPTHSD17B10RECQL | |
| (+)-Taxifolin SCHEMBL29368246 | 1.00 | CYP3A4 (1.00) | CYP3A4ALOX15MAPTHSD17B10RECQL | |
| (+)-Taxifolin SCHEMBL1707803 | 1.00 | CYP3A4 (1.00) | CYP3A4ALOX15MAPTHSD17B10RECQL | |
| (+)-Taxifolin SCHEMBL7628142 | 1.00 | CYP3A4 (1.00) | CYP3A4ALOX15MAPTHSD17B10RECQL | |
| (+)-Taxifolin SCHEMBL296323 | 1.00 | CYP3A4 (1.00) | CYP3A4ALOX15MAPTHSD17B10RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117384217-B | Preparation method of composite phosphorus-free water treatment corrosion inhibitor | 湖南星君水伯新能源有限公司 | 2025-05-16 | — | — | CN | claimed |
| CN-117384217-A | Preparation method of composite phosphorus-free water treatment corrosion inhibitor | 广东天祺环保科技有限公司 | 2024-01-12 | — | — | CN | claimed |
| WO-2023064318-A1 | BIPHASIC COMPOSITIONS COMPRISING ONE OR BOTH OF CARBONATE AND PHOSPHATE | Natural Extraction Systems, LLC (US) | 2023-04-20 | — | — | WO | claimed |
| WO-2022182527-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| US-20250241889-A1 | FORTIFIED WATER | LOVANESS LTD (GB) | 2025-07-31 | — | — | US | disclosed |
| CN-117384217-B | Preparation method of composite phosphorus-free water treatment corrosion inhibitor | 湖南星君水伯新能源有限公司 | 2025-05-16 | — | — | CN | disclosed |
| CN-119424405-A | Application of taxifolin in preparation of product for inhibiting expression of uric acid transporter | 深圳市第二人民医院(深圳市转化医学研究院) | 2025-02-14 | — | — | CN | disclosed |
| CN-119331888-A | Polygonatum cyrtonema PcF3H gene and application thereof in promotion of synthesis of dihydroflavonoid compounds and catalysis of naringenin hydroxylation | 浙江农林大学 | 2025-01-21 | — | — | CN | disclosed |
| EP-4484952-A2 | OPTIMIZED PEPTIDES FOR TARGETING HUMAN NERVES AND THEIR USE IN IMAGE GUIDED SURGERY, DIAGNOSTICS AND THERAPEUTIC DELIVERY | The Regents of the University of California (US) | 2025-01-01 | — | — | EP | disclosed |
| EP-3661539-B1 | OPTIMIZED PEPTIDES FOR TARGETING HUMAN NERVES AND THEIR USE IN IMAGE GUIDED SURGERY, DIAGNOSTICS AND THERAPEUTIC DELIVERY | UNIV CALIFORNIA (US) | 2024-10-09 | — | — | EP | disclosed |
| EP-4422417-A1 | FORTIFIED WATER | Lovaness Limited (GB) | 2024-09-04 | — | — | EP | disclosed |
| CN-118453453-A | Efficient anti-chapping hand cream containing sheep oil and preparation method thereof | 严志华 | 2024-08-09 | — | — | CN | disclosed |
| EP-4041311-A1 | METHODS AND SYSTEMS USING PEPTIDES FOR TARGETING AND MAPPING HUMAN NERVES IN IMAGE GUIDED SURGERY, DIAGNOSTICS AND THERAPEUTIC DELIVERY | Alume Biosciences, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
| WO-2022123587-A1 | A FORMULATION AND/OR COMBINATION TO PREVENT PULMONARY DISEASES INCLUDING SARS-COV-2 | GOEL, PAWAN KUMAR (IN) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022120177-A1 | NERVE TARGETING PEPTIDES AND METHODS OF USE | ALUME BIOSCIENCES, INC. (US) | 2022-06-09 | — | — | WO | disclosed |
| US-11292758-B2 | Compounds and methods for delivery of prostacyclin analogs | UNITED THERAPEUTICS CORPORATION (US) | 2022-04-05 | — | — | US | disclosed |
| CN-111218406-B | Mucor circinelloides MF-8 and application thereof in improving content of taxifolin in rhizoma smilacis glabrae | 浙江工业大学 | 2022-03-15 | — | — | CN | disclosed |
| CN-113214210-B | Preparation method of dihydroquercetin | 合肥立方制药股份有限公司 | 2022-03-04 | — | — | CN | disclosed |
| CN-114031656-A | Medicine for treating urinary calculus related diseases and preparation method thereof | 张弘 | 2022-02-11 | — | — | CN | disclosed |
| US-20220024845-A1 | COMPOUNDS AND METHODS FOR DELIVERY OF PROSTACYCLIN ANALOGS | UNITED THERAPEUTICS CORPORATION (US) | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024845-A1 | COMPOUNDS AND METHODS FOR DELIVERY OF PROSTACYCLIN ANALOGS | PTGIR, PTGIS, PGF | CYP3A4 3256/4885ALOX15 54/4885MAPT 4705/4885 |
| US-11292758-B2 | Compounds and methods for delivery of prostacyclin analogs | PTGIR, PTGIS, PGF | CYP3A4 2603/4885ALOX15 46/4885MAPT 4720/4885 |
| US-20250241889-A1 | FORTIFIED WATER | AQP1, AQP3, ADH1B | CYP3A4 1756/4885ALOX15 1704/4885MAPT 3358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.